Ambarish Pandey, MD
Cardiovascular Disease · Dallas, TXNPI 1891084729
Payments from drug & device makers
Across 1,030 payments — averaging $2842.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Roche Diagnostics Corporation$1.2M
- Applied Therapeutics, Inc.$393K
- Scpharmaceuticals Inc.$279K
- Novo Nordisk AS$189K
- E.r. Squibb & Sons, L.L.C.$163K
- Boehringer Ingelheim International GmbH$158K
- plus $511K from 24 others
Across 33 payments — averaging $11,891 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Applied Therapeutics, Inc.$379K
- Pfizer$14K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Roche Diagnostics Corporation | 25 | $1,234,804 |
| Applied Therapeutics, Inc. | 5 | $392,550 |
| Scpharmaceuticals Inc. | 6 | $279,026 |
| Novo Nordisk AS | 637 | $189,155 |
| E.r. Squibb & Sons, L.L.C. | 4 | $163,033 |
| Boehringer Ingelheim International GmbH | 136 | $158,009 |
| Gilead | 2 | $130,000 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 8 | $67,841 |
| Roche Diagnostics International Ltd | 11 | $52,882 |
| Bayer | 30 | $36,480 |
| Novo Nordisk | 21 | $33,908 |
| Eli Lilly | 52 | $31,678 |
| Amgen | 1 | $27,916 |
| Pfizer | 12 | $23,974 |
| Boehringer Ingelheim | 21 | $23,913 |
| Edwards Lifesciences | 7 | $21,484 |
| Alnylam Pharmaceuticals Inc. | 11 | $15,507 |
| Abbott | 7 | $10,134 |
| Merck | 5 | $8,425 |
| AstraZeneca | 11 | $7,217 |
| Idorsia Pharmaceuticals US Inc | 1 | $6,440 |
| Kilele Health Inc | 1 | $5,000 |
| Medtronic | 9 | $4,861 |
| Novartis | 1 | $2,400 |
| Altathera Pharmaceuticals LLC | 1 | $600 |
| Roche Diabetes Care, Inc. | 1 | $141 |
| Anumana, Inc. | 1 | $125 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $98 |
| Esperion Therapeutics, Inc. | 1 | $52 |
| Mindray DS USA, Inc. | 1 | $15 |
How this compares
$2,927,667 in reported general payments places this provider in the 95th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Dallas
- Ramin Farzaneh-FarDallas$17.1M
- Jeffrey GladdenDallas$15.8M
- Ann NavarDallas$14.5M
- Justin GrodinDallas$6.2M
- Paul GrayburnDallas$1.8M
- Parag KaleDallas$1.5M
- Eric PetersonDallas$1.4M
- Parag JoshiDallas$1.4M
- Darren McGuireDallas$1.3M
- Peter McCulloughDallas$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.